Information on chemotherapy and hormone therapy from tumor registry had moderate agreement with chart reviews

Xianglin L. Du, Charles R. Key, Lois Dickie, Ronald Darling, George L. Delclos, Kim Waller, Dong Zhang

Research output: Contribution to journalArticle

31 Citations (Scopus)

Abstract

Background: Surveillance, Epidemiology, and End Results (SEER) cancer registries provide accurate information on cancer surgery and radiation, but the validity of registry data on chemotherapy and hormone therapy for breast cancer has not been well studied. We validated the registry data for chemotherapy and hormone therapy against an independent medical chart review. Methods: We identified 1,228 women diagnosed with breast cancer at age >=65 in 1993-1999 in the New Mexico SEER Tumor Registry and completed medical chart reviews. Results: Overall, there was moderate agreement between these two databases on chemotherapy that was received within 6 months of diagnosis. The observed agreement was 96.0%, with a kappa of 0.72 (95% confidence interval: 0.64-0.79). The sensitivity of the registry data for chemotherapy was 70.7% and the specificity was 98.2%. The positive predictive value of the registry data for chemotherapy was 77.8%. The sensitivity of the registry data for hormone therapy was 59.7%, and the specificity was 89.5%. The observed agreement for hormone therapy was 80.0%, with a kappa of 0.52 (0.46-0.57). Conclusion: Agreement on chemotherapy and hormone therapy between the New Mexico SEER Tumor Registry and chart reviews was moderate. The preferred approach would be to combine data from different sources to obtain more complete information.

Original languageEnglish (US)
Pages (from-to)53-60
Number of pages8
JournalJournal of Clinical Epidemiology
Volume59
Issue number1
DOIs
StatePublished - Jan 2006

Fingerprint

Registries
Hormones
Drug Therapy
Neoplasms
Epidemiology
Therapeutics
Breast Neoplasms
Information Storage and Retrieval
Databases
Confidence Intervals
Radiation

Keywords

  • Breast cancer
  • Chart review
  • Chemotherapy
  • Hormone therapy
  • SEER
  • Tumor registry

ASJC Scopus subject areas

  • Medicine(all)
  • Public Health, Environmental and Occupational Health
  • Epidemiology

Cite this

Information on chemotherapy and hormone therapy from tumor registry had moderate agreement with chart reviews. / Du, Xianglin L.; Key, Charles R.; Dickie, Lois; Darling, Ronald; Delclos, George L.; Waller, Kim; Zhang, Dong.

In: Journal of Clinical Epidemiology, Vol. 59, No. 1, 01.2006, p. 53-60.

Research output: Contribution to journalArticle

Du, Xianglin L. ; Key, Charles R. ; Dickie, Lois ; Darling, Ronald ; Delclos, George L. ; Waller, Kim ; Zhang, Dong. / Information on chemotherapy and hormone therapy from tumor registry had moderate agreement with chart reviews. In: Journal of Clinical Epidemiology. 2006 ; Vol. 59, No. 1. pp. 53-60.
@article{9d92d255dcf549c79dd1104e2b98bddd,
title = "Information on chemotherapy and hormone therapy from tumor registry had moderate agreement with chart reviews",
abstract = "Background: Surveillance, Epidemiology, and End Results (SEER) cancer registries provide accurate information on cancer surgery and radiation, but the validity of registry data on chemotherapy and hormone therapy for breast cancer has not been well studied. We validated the registry data for chemotherapy and hormone therapy against an independent medical chart review. Methods: We identified 1,228 women diagnosed with breast cancer at age >=65 in 1993-1999 in the New Mexico SEER Tumor Registry and completed medical chart reviews. Results: Overall, there was moderate agreement between these two databases on chemotherapy that was received within 6 months of diagnosis. The observed agreement was 96.0{\%}, with a kappa of 0.72 (95{\%} confidence interval: 0.64-0.79). The sensitivity of the registry data for chemotherapy was 70.7{\%} and the specificity was 98.2{\%}. The positive predictive value of the registry data for chemotherapy was 77.8{\%}. The sensitivity of the registry data for hormone therapy was 59.7{\%}, and the specificity was 89.5{\%}. The observed agreement for hormone therapy was 80.0{\%}, with a kappa of 0.52 (0.46-0.57). Conclusion: Agreement on chemotherapy and hormone therapy between the New Mexico SEER Tumor Registry and chart reviews was moderate. The preferred approach would be to combine data from different sources to obtain more complete information.",
keywords = "Breast cancer, Chart review, Chemotherapy, Hormone therapy, SEER, Tumor registry",
author = "Du, {Xianglin L.} and Key, {Charles R.} and Lois Dickie and Ronald Darling and Delclos, {George L.} and Kim Waller and Dong Zhang",
year = "2006",
month = "1",
doi = "10.1016/j.jclinepi.2005.06.002",
language = "English (US)",
volume = "59",
pages = "53--60",
journal = "Journal of Clinical Epidemiology",
issn = "0895-4356",
publisher = "Elsevier USA",
number = "1",

}

TY - JOUR

T1 - Information on chemotherapy and hormone therapy from tumor registry had moderate agreement with chart reviews

AU - Du, Xianglin L.

AU - Key, Charles R.

AU - Dickie, Lois

AU - Darling, Ronald

AU - Delclos, George L.

AU - Waller, Kim

AU - Zhang, Dong

PY - 2006/1

Y1 - 2006/1

N2 - Background: Surveillance, Epidemiology, and End Results (SEER) cancer registries provide accurate information on cancer surgery and radiation, but the validity of registry data on chemotherapy and hormone therapy for breast cancer has not been well studied. We validated the registry data for chemotherapy and hormone therapy against an independent medical chart review. Methods: We identified 1,228 women diagnosed with breast cancer at age >=65 in 1993-1999 in the New Mexico SEER Tumor Registry and completed medical chart reviews. Results: Overall, there was moderate agreement between these two databases on chemotherapy that was received within 6 months of diagnosis. The observed agreement was 96.0%, with a kappa of 0.72 (95% confidence interval: 0.64-0.79). The sensitivity of the registry data for chemotherapy was 70.7% and the specificity was 98.2%. The positive predictive value of the registry data for chemotherapy was 77.8%. The sensitivity of the registry data for hormone therapy was 59.7%, and the specificity was 89.5%. The observed agreement for hormone therapy was 80.0%, with a kappa of 0.52 (0.46-0.57). Conclusion: Agreement on chemotherapy and hormone therapy between the New Mexico SEER Tumor Registry and chart reviews was moderate. The preferred approach would be to combine data from different sources to obtain more complete information.

AB - Background: Surveillance, Epidemiology, and End Results (SEER) cancer registries provide accurate information on cancer surgery and radiation, but the validity of registry data on chemotherapy and hormone therapy for breast cancer has not been well studied. We validated the registry data for chemotherapy and hormone therapy against an independent medical chart review. Methods: We identified 1,228 women diagnosed with breast cancer at age >=65 in 1993-1999 in the New Mexico SEER Tumor Registry and completed medical chart reviews. Results: Overall, there was moderate agreement between these two databases on chemotherapy that was received within 6 months of diagnosis. The observed agreement was 96.0%, with a kappa of 0.72 (95% confidence interval: 0.64-0.79). The sensitivity of the registry data for chemotherapy was 70.7% and the specificity was 98.2%. The positive predictive value of the registry data for chemotherapy was 77.8%. The sensitivity of the registry data for hormone therapy was 59.7%, and the specificity was 89.5%. The observed agreement for hormone therapy was 80.0%, with a kappa of 0.52 (0.46-0.57). Conclusion: Agreement on chemotherapy and hormone therapy between the New Mexico SEER Tumor Registry and chart reviews was moderate. The preferred approach would be to combine data from different sources to obtain more complete information.

KW - Breast cancer

KW - Chart review

KW - Chemotherapy

KW - Hormone therapy

KW - SEER

KW - Tumor registry

UR - http://www.scopus.com/inward/record.url?scp=29144461772&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=29144461772&partnerID=8YFLogxK

U2 - 10.1016/j.jclinepi.2005.06.002

DO - 10.1016/j.jclinepi.2005.06.002

M3 - Article

VL - 59

SP - 53

EP - 60

JO - Journal of Clinical Epidemiology

JF - Journal of Clinical Epidemiology

SN - 0895-4356

IS - 1

ER -